Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase II, Randomized, Observer-Blind, Single Center, Controlled Study of Two Doses of Various Formulations of Walter Reed Army Institute of Research (WRAIR) Live Attenuated Tetravalent Dengue Vaccine Compared to Placebo Control Administered on 0-6-Month Schedule, to Healthy Adults

Trial Profile

Phase II, Randomized, Observer-Blind, Single Center, Controlled Study of Two Doses of Various Formulations of Walter Reed Army Institute of Research (WRAIR) Live Attenuated Tetravalent Dengue Vaccine Compared to Placebo Control Administered on 0-6-Month Schedule, to Healthy Adults

Completed
Phase of Trial: Phase II

Latest Information Update: 02 Nov 2018

At a glance

  • Drugs TDENV LAV (Primary)
  • Indications Dengue
  • Focus Adverse reactions; Pharmacodynamics
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 06 Apr 2008 Status changed from in progress to completed, as reported by ClinicalTrials.gov.
    • 25 Nov 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top